CUMULATIVE INDEX 1997

Volume 17

February	OCULAR ALLERGY, pages 1–183
May	ALLERGIC DISEASE IN AIDS, pages 185–343
August	CONTACT DERMATITIS, pages 345–511
November	TREATMENT OF ASTHMA AND ALLERGIC DISEASE IN THE ELDERLY, pages 513–764

Note: Page numbers of article titles are in **boldface** type

Acetylation disorders, drug reactions in, 322
N-Acetylcysteine, in contact dermatitis, 408
Acne vulgaris, in HIV infection, 249
Acneiform eruptions, in irritant contact dermatitis, 372
Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection.*
Acral lentiginous melanoma, in elderly persons, 538
Actinic dermatitis, chronic, 465–468
Actinic keratosis, in elderly persons, 538
Actinic purpura, in elderly persons, 532
Acyclovir, reactions to, in HIV infection, 334
Adenosine, in cardiovascular disease, in elderly persons, with asthma, 632–633
Age, as factor in vernal conjunctivitis, 34
Aging, physiologic changes of, 516
  asthma and, 571, 676–677
  exercise capacity and, 609–610
  immune system, 516–519, 672–674
  postoperative function and, 660
AIDS. See *Human immunodeficiency virus infection.*
Airway obstruction, upper, versus asthma, in elderly persons, 568–569
Airway resistance, preoperative minimizing of, in asthma, in elderly persons, 666–667
Alendronate, in glucocorticoid-induced osteoporosis, 706
Allergen immunotherapy, in HIV infection, **303–317**
  clinical trials of, 310–313
  disease types in, 306–308
  efficacy of, 308–309
  for allergic rhinitis, 299–300
  immunopathophysiologic considerations in, 304–306
  versus vaccination, 309–310
Allergic bronchopulmonary aspergillosis, asthma and, in elderly persons, 681–682
Allergic conjunctivitis, **19–31**
  allergen sources in, 19
  chemosis and injection in, 23
  diagnosis of, 25–26, 161
  examination in, 22–24
  in children, 162–164
  incidence of, 19
  itching in, 21
  late-phase reaction in, 26–27
  mast cells in, 9–11, 19–20
  patient history in, 20–22
  perennial, 25
  periorbital edema in, 23
  seasonal, 24
  symptoms of, 21
  treatment of, 27–29, 162–164
Allergic contact dermatitis. See *Contact dermatitis, allergic.*
Allergic disease, drug reactions, 320–321
  eosinophilia in, 210–211, 218–219
  in elderly persons. See *Elderly persons.*
  in HIV infection, bronchopulmonary aspergillosis, eosinophilia in, 221
  clinical features of, 307
  granulomatosis with angiitis, eosinophilia in, 219–220

Allergic disease *(Continued)*
skin tests for, 279–281
treatment of, 307–308
ocular. See *Ocular allergy.*
of eyelids, 106
Allergic rhinitis, in elderly persons, 514, 544
in HIV infection, **291–301**
asthma with, 297
atopy in, 294–296
complications of, 292–293
conjunctivitis with, 296
eosinophilia in, 218
evaluation of, 292
immunotherapy for, 299–300
in pediatric patients, 297–298
pathophysiology of, 291–292
sinusitis with, 298–299
treatment of, 293–294
Allergy testing, in asthma, in elderly persons, 565
in vernal conjunctivitis, 41
Allokinesis, in atopic dermatitis, 434
Alloys, for implants. See *Metals, in implants.*
Amalgam dental fillings, contact stomatitis from, 475–476
Amiloride, in contact dermatitis, 408
Amines, biogenic, 2
Aminopenicillins, reactions to, in HIV infection, 324, 328
Amiodarone, in cardiovascular disease, in elderly persons, with asthma, 632
Anaphylaxis, in latex allergy, 480–481
Anergy, clonal, in contact dermatitis resolution, 395–398
Anesthetics, topical, contact stomatitis from, 478
Angiitis, microscopic, pulmonary involvement in, 738
Angioedema, of eyelids, 116–117
Angiokeratoma, in elderly persons, 540
Angioma, cherry, 540
Angiotensin-converting enzyme inhibitors, in asthma, 593–594
in cardiovascular disease, in elderly persons, with asthma, 632
Angular cheilitis, in elderly persons, 530–531
Ankylosing spondylitis, pulmonary involvement in, in elderly persons, 730
Antacids, in gastroesophageal reflux, in elderly persons, 649
Antazoline, in allergic conjunctivitis, 27
Antiarrhythmics, in cardiovascular disease, in elderly persons, with asthma, 632–633
Antibiotics, in pneumonia, in asthma, in elderly persons, 687–691
in sinusitis, in elderly persons, 552–553
photocontact dermatitis from, 453, 459
Antibodies, to HIV, appearance of, 187
formation of, 233
tests for, 190–192
Anticholinergic drugs, in asthma, in elderly persons, cardiovascular effects of, 636–637
preoperative inhalation of, 668
Antigens, in photocontact dermatitis, 455–457
for photopatch testing, 460, 463–464
Antihistamines, in allergic conjunctivitis, 27
in allergic rhinitis, in HIV infection, 293
in asthma, in elderly persons, cardiovascular effects of, 640
in contact stomatitis, 483
in mast cell–mediated disease, 76
in rhinitis, in elderly persons, 546
in vernal conjunctivitis, 44
Anti-inflammatory drugs, in mast cell–mediated disease, 81–82
in rhinitis, in elderly persons, 547
in vernal conjunctivitis, 45–46
Antimycobacterials, reactions to, in HIV infection, 329, 334
Antineutrophil cytoplasmic antibody, in systemic vasculitis, 736–738
Antireflux surgery, in elderly persons, asthma and, 650–651, 654–655
Antirheumatic drugs, pulmonary effects of, 738–739
Antiseptics, contact stomatitis from, 478
Antisynthetase syndrome, pulmonary involvement in, 734
Antral puncture, in sinusitis, in HIV infection, 285
Arteritis, giant cell/temporal, pulmonary involvement in, in elderly persons, 735–736
Arthritis, psoriatic, pulmonary involvement in, in elderly persons, 730
reactive, pulmonary involvement in, in elderly persons, 730
Aspergillosis, in elderly persons, asthma and, 681–682
in HIV infection, allergic bronchopulmonary, eosinophilia in, 221
asthma and, 258
paranasal sinus, 276
Aspiration, of gastrointestinal contents, asthma and, in elderly persons, 570–571, 646
Aspirin, in mast cell–mediated disease, 81–82
rhinitis from, 545
sensitivity to, in elderly persons, 554, 596–597, 633

Astemizole, in asthma, in elderly persons, cardiovascular effects of, 640
Asthma, cardiac. See *Cardiac asthma.*
in elderly persons, 581–584
atopy in, 576, 581–582
bronchial hyperresponsiveness in, 575–576
causes of, 561–562
chronic bronchitis and, 583–584
clinical features of, 560–561, 577–580
exercise-induced, 616–617
comorbidities with, 561
corticosteroid effects on, 595–596
definition of, 558, 588–589
demographics of, 671–672
depression with, 596, 615
diagnosis of, **587–605**
differential diagnosis of, **557–574**, 590–592, 628–630
drug responses in, 572
drug-induced, 592–593, 595–597
from antirheumatic agents, 738–739
from glucocorticoids, **701–726**
eosinophilia and, 582
epidemiology of, 513–514, 558–559
new onset, 580–581
pneumonia and, 671–672
with cardiovascular disease, 627–628
exercise and, **607–626**
gastroesophageal reflux and, 570–571, 594–595, **645–658**
histopathology of, 588–589
history taking in, 561–562
hypertension with, 593–594
immunology of, 675–676
laboratory studies in, 562–566
lower respiratory tract infections with, **671–700**
nasal polyposis and, 545, 576, 582
natural history of, 559–560
new onset, 559, **575–586**
nonallergic, 545, 576–577
pathogenesis of, 514
pathophysiology of, 581–584
patient education on, 601–602
physical activity level in, 614–616
physical disability from, 607–609
physical examination in, 562
physiology of aging and, 571, 676–677
presurgical preparation with, **659–670**
severity of, 561
sinusitis and, 553–554, 582, 592
smoking and, 559, 583–584, 666–667
treatment of, **587–605**
airway response in, 572, 583
cardiovascular disorders and, **627–644**
drug delivery methods for, 601
endocrine-metabolic effects of, **701–726**
exercise training in, 618–621
gastroesophageal reflux and, 647, 651–654
goals of, 597
triggering factors in, 589–590
versus bronchiectasis, 569
versus bronchogenic carcinoma, 570
versus cardiac disease, 570, 592
versus central airways obstruction, 591–592
versus chronic obstructive pulmonary disease, 567–568, 584, 591
versus extrathoracic obstruction, 590–591
versus gastrointestinal disorders, 570–571
versus infections, 591
versus interstitial lung disease, 569
versus pulmonary embolism, 569–570
versus upper airway obstruction, 568–569
in HIV infection, **253–266**
allergic rhinitis with, 297
differential diagnosis of, 255–259
eosinophilia in, 218, 221
epidemiology of, 253–254
proinflammatory factors in, 254–255
pulmonary function testing in, 259–262
treatment of, 263–264
Ataxia-telangiectasia, in children, 175–176
Atelectasis, postoperative, 660–662
Athlete's foot, versus contact dermatitis, 529
Atopic dermatitis, **431–441**
dust mites in, clinical features of, 432–435
patch testing in, 437–439
role of, 435–437
Atopic keratoconjunctivitis, versus vernal conjunctivitis, 40
Atopy, asthma in, in elderly persons, 576, 581–582
in HIV infection, 306–308
allergen immunotherapy for. See *Allergen immunotherapy.*
allergic rhinitis in, 294–296
sinusitis in, 278–279
of eyelid skin, 123–124
Atrophic rhinitis, in elderly persons, 545–546
Autoantibodies, in elderly persons, 518
Autoimmune subepithelial blistering diseases, with ocular involvement, **139–159**. See also specific diseases, e.g., *Cicatricial pemphigoid.*
Autosensitization, contact dermatitis in, 524

B lymphocytes, aging effects on, 673

Bacillus Calmette-Guerin vaccine, in HIV infection, 203
Bacterial conjunctivitis, clinical features of, 166–167
in children, 164–166
treatment of, 167–168
Barrier, epidermal. See *Epidermal permeability barrier.*
Basal cell carcinoma, in elderly persons, 533–534
of eyelids, 114, 119–120
Belsey Mark IV repair, in gastroesophageal reflux, in elderly persons, 651, 655
Benzocaine, contact stomatitis from, 478
Beta agonists, in asthma, in elderly persons, 598–600
cardiovascular effects of, 634–636
preoperative inhalation of, 667
response to, 583
Beta-blockers, in cardiovascular disease, with asthma, 630–631
in glaucoma, asthma from, 593
in hypertension, with asthma, 594
Biogenic amines, 2
Birbeck granules, in Langerhans cells, 387
Bisphosphonates, in glucocorticoid-induced osteoporosis, 706
Blackheads, of eyelids, 113
Blood gas evaluation, preoperative, in asthma, in elderly persons, 665
Blushing syndrome, 112–113
Bonding agents, for dental procedures, contact stomatitis from, 477
Bone metabolism, glucocorticoid effects on, in elderly persons, 704–708, 715–717
Breathing exercises, preoperative, in asthma, in elderly persons, 666
Bronchial asthma. See *Asthma.*
Bronchial hyperresponsiveness, asthma and, in elderly persons, 575–576, 679–681
Bronchiectasis, in HIV infection, 255
versus asthma, in elderly persons, 569
Bronchiolitis obliterans, in rheumatoid arthritis, in elderly persons, 729–730
in systemic lupus erythematosus, in elderly persons, 732
Bronchitis, chronic, asthma and, in elderly persons, 583–584
Bronchocentric granulomatosis, in HIV infection, eosinophilia in, 221
Bronchodilators, in asthma, in elderly persons, 572, 598–600
Bronchogenic carcinoma, in HIV infection, wheezing in, 258
versus asthma, in elderly persons, 570
Bronchoprovocation challenge test, in asthma, in elderly persons, 565
Bronchospasm, exercise-induced, 616–617
Budesonide, in asthma, endocrine-metabolic effects of, in elderly persons, 710–718
Burns, irritant contact dermatitis in, 371–372
stomatitis in, 472

Calcitonin, in glucocorticoid-induced osteoporosis, 706–707
Calcium, in glucocorticoid-induced osteoporosis, 706
Calcium channel blockers, in cardiovascular disease, with asthma, 632
in hypertension, with asthma, 594
Cancer, in elderly persons, lung, versus asthma, 570
skin, versus allergic disease, 532–540
in HIV infection, eosinophilia in, 220
wheezing in, 258
Candidiasis, from dentures, versus contact stomatitis, 479
in HIV infection, 189–190
Caplan's syndrome, 730
Carcinoma, in elderly persons, basal cell, 533–534
bronchogenic, versus asthma, 570
squamous cell, cutaneous, 534–536
in HIV infection, eosinophilia in, 220
Cardiac asthma, in elderly persons, 570, 592
versus primary asthma, 628–630
Cardiomyopathy, in HIV infection, eosinophilia in, 223
wheezing in, 258
Cardiovascular disease, in elderly persons, asthma with, **627–644**
asthma drug cardiovascular side effects in, 633–640
cardiac drugs appropriate for, 630–633
case study of, 630
epidemiology of, 627–628
versus asthma, 570, 592, 628–630
Cathepsin G, description of, 4
CD antigens, expression of, in Langerhans cells, 387–388
Cellulitis, eosinophilic, in HIV infection, 222
Cetirizine, in asthma, cardiovascular effects of, in elderly persons, 640
in mast cell–mediated disease, 77
Chalazion, of eyelids, 118–119
Cheilitis, angular, in elderly persons, 530–531
Chemical injury, stomatitis in, 472
Cherry angioma, 540
Chest drainage, preoperative, in asthma, in elderly persons, 666

Chickenpox vaccine, in HIV infection, 202–203
Children. See *Pediatric patients.*
Chlamydia pneumoniae, asthma and, 678–679
Chromium, allergic reactions to, 488, 491
patch testing for, 496
in alloys, contact stomatitis from, 476
stainless steel, 489
vitallium, 489
Chronic obstructive pulmonary disease, in elderly persons, physical disability from, 607–609
reversible component of, 613
treatment of, exercise training in, 621
versus asthma, 567–568, 584, 591
Churg-Strauss syndrome, in HIV infection, eosinophilia in, 219–220
pulmonary involvement in, 737–738
Chymase, description of, 4
Cicatricial pemphigoid, 141–148
clinical presentation of, 141–142
course of, 147–148
differential diagnosis of, 145–146
laboratory investigations in, 143–145
pathogenesis of, 146–147
treatment of, 147–148
Cimetidine, in gastroesophageal reflux, in elderly persons, asthma and, 595, 649–650, 655
Ciprofloxacin, reactions to, in HIV infection, 330
Clindamycin, reactions to, in HIV infection, 327, 333
Clinical lesions, of eyelids, 104–105
Clonal anergy, of T lymphocytes, in contact dermatitis resolution, 395–398
Clothing, protective, for contact dermatitis prevention, 445
Cobalt, allergic reactions to, 488, 491
patch testing for, 496
cell degranulation from, 499
in alloys, contact stomatitis from, 476
in vitallium, 489
Coccidioidomycosis, in HIV infection, eosinophilia in, 218
Collagen vascular disease, in HIV infection, eosinophilia in, 219–220
Comedones, of eyelids, 113
Complement system, in asthma, in HIV infection, 254–255
Computed tomography, in asthma, in elderly persons, 566
Congenital glaucoma, in children, 172–173
Congestive heart failure, versus primary asthma, in elderly persons, 570, 628–630
Conjunctiva, description of, 19
Conjunctival deposition, eye irritation due to, 133–134
Conjunctivitis, allergic. See *Allergic conjunctivitis.*
allergic rhinitis with, in HIV infection, 296
bacterial. See *Bacterial conjunctivitis.*
drug hypersensitivity–related, versus vernal conjunctivitis, 41
giant papillary. See *Giant papillary conjunctivitis.*
in neonates, 168–169
seasonal, versus vernal conjunctivitis, 40–41
vernal. See *Vernal conjunctivitis.*
Connective-tissue mast cells, 6
Contact dermatitis, acute, of eyelids, 121–122
allergic, agents causing, 379–380
in photosensitivity, 459–460
clinical features of, in photosensitivity, 452, 458
cytokines in, 362–363, 391–397
drugs inhibiting, 408
dust mites in, **431–441**
epidemiology of, in photosensitivity, 457–458
histology of, 361–362, 381, 407–408
immunologic mechanisms of, 385–396
keratinocyte products in, 391–395
Langerhans cells in, 386–391
overview of, 385–386
T lymphocytes in, 386, 395–398, 409–410
in elderly persons, 521–530
causes of, 522–525
clinical features of, 526
diagnosis of, 527–528
differential diagnosis of, 528–530
systemic, 525–526
treatment of, 527–528
versus irritant contact dermatitis, 521–522, 526–527
in light sensitivity. See *Photocontact dermatitis.*
in photosensitivity, 451–452, 454–460
irritant dermatitis with, 367
metal implants in, **487–504**
of eyelids, 118
of oral mucous membrane. See *Contact stomatitis.*
pathogenesis of, 361–363, 378–379, 408–409
pathophysiology of, **377–405**
in photosensitivity, 454–457
photopatch testing in, 460–465
predisposition to, 379
prevention of, **443–450**
resolution of, clonal anergy in, 395, 397–398
T lymphocytes in, 386, 395–398, 409–410

Contact dermatitis *(Continued)*
treatment of, drugs in, 408
versus irritant contact dermatitis, **359–364**, 365, 381–384
in elderly persons, 521–522, 526–527
in photosensitivity, 451
atopic, dust mites in, **431–441**
causes of, 131
chronic, of eyelids, 123–126
clinical features of, 380–381
cosmetics and, 131–134
eye irritation due to, 136–137
irritant, acute, 366–368
acute delayed, 368–369
agents causing, 378
airborne, 366
in photosensitivity, 453–454
versus clinical type, 365–373
allergic dermatitis with, 367
animal studies of, 409
clinical features of, **365–375**
in photosensitivity, 452
versus clinical type, 367–373
cumulative, 370–371
cytokines in, 362–363, 408–409, 411–412
definition of, 359, 365
diagnosis of, in photosensitivity, 452, 454
drugs inhibiting, 408
economic impact of, 353
epidemiology of, 346–351
epidermal permeability barrier and, **417–430**
exsiccation eczematid, 371
heat shock proteins in, 410–411
histology of, 361–362, 381, 407–408
in light sensitivity. See *Photocontact dermatitis.*
interleukin-15 in, 411–412
irritant reaction, 369
leukocyte mediators in, **407–415**
manifestation threshold in, 370–371
nonerythematous, 372
pathogenesis of, 361–363, 408–409
cumulative factors in, 370–371
epidermal permeability barrier and, **417–430**
pathophysiology of, **377–405**
prevention of, 351–353
education for, 447–448
protective gloves and clothing in, 445
screening programs for, 447
skin care products in, 445–447
technical measures in, 444–445
prognosis for, 351–353
public health impact of, **345–357**
pustular and acneiform, 372
subjective (sensory), 373
T lymphocytes in, 409
traumatic, 371–372
traumiterative, 371
treatment of, drugs in, 408
versus allergic contact dermatitis, **359–364**, 365, 381–384
in elderly persons, 521–522, 526–527
in photosensitivity, 451
medications and, 134–135
occupational. See *Occupational dermatitis.*
of eye, **131–138**
photocontact. See *Photocontact dermatitis.*
spectrum of, 378–381
Contact lenses, classification of, 60–61
coated, 64–66
Contact sensitization, Langerhans cells in, 389
Contact stomatitis, **471–485**
allergic, antiseptics in, 478
clinical features of, 472
dental impression compounds in, 477
dental products in, 474
dentures in, 478–479
diagnosis of, 482
differential diagnosis of, 481–482
drug formulation additives in, 478
latex in, 480–481
metals in, 474–477
mouth-care products in, 474
perioral dermatitis with, 472
preservatives in, 478
rubber chemicals in, 480–481
topical anesthetics in, 478
treatment of, 482–483
clinical features of, 471–472
in chemical injury, 472–473
in traumatic injury, 472–473
Contact urticaria, 380
Corneal shield ulcers, in vernal conjunctivitis, 47
Coronary angioplasty, in cardiovascular disease, in elderly persons, with asthma, 631–632
Coronary artery bypass surgery, in cardiovascular disease, in elderly persons, with asthma, 631–632
Corticosteroids. See also *Glucocorticoids.*
contact dermatitis from, 474, 525
in allergic conjunctivitis, 28
in allergic rhinitis, in HIV infection, 293
in asthma, in elderly persons, 595–596, 600–601
cardiovascular effects of, 638–639
endocrine-metabolic effects of, **701–726**
preoperative, 668
in HIV infection, 263
in contact stomatitis therapy, 408, 483
in drug reactions, in HIV infection, 325
in mast cell–mediated disease, 82

in sinusitis, in elderly persons, 552
in vernal conjunctivitis, 46
Cosmetics, contact dermatitis and, 131–134
Costs, of contact dermatitis, 353
Cough, in asthma, 560–561, 577–580
in temporal arteritis, 735
Creams, protective, for contact dermatitis prevention, 445–447
Crescendo phenomenon, in irritant dermatitis, 367
CREST syndrome, pulmonary involvement in, in elderly persons, 733–734
Cricoarytenoiditis, versus asthma, in elderly persons, 569
Cromolyn sodium, in allergic conjunctivitis, 27–28
in asthma, in elderly persons, cardiovascular effects of, 639
preoperative, 668–669
in mast cell–mediated disease, 79–80
in vernal conjunctivitis, 45
Cryotherapy, for vernal conjunctivitis, 47
Culture, of human immunodeficiency virus, 191
Cumulative irritant contact dermatitis, 370–371
Cyclosporine, in allergic conjunctivitis, 29
in vernal conjunctivitis, 47
Cyst(s), skin, in elderly persons, 540–541
Cytokines, description of, 5
in contact dermatitis, allergic, 362–363, 391–397, 408–409
irritant, 362–363, 408–409, 411–412
in eosinophil activation, 208
in epidermal permeability barrier, 422–425
in disruption, 425, 427
of keratinocytes, in contact dermatitis, 362–363, 391–397, 408–409, 411–412
in Langerhans cell survival, 391
of T lymphocytes, 409–410
production of, in HIV infection, 232–233, 235, 304–306
receptors for, in epidermal permeability barrier, 425

Dapsone, reactions to, in HIV infection, 326–327, 332
Decongestants, in mast cell–mediated disease, 76–77
in rhinitis, in elderly persons, 546–547
in sinusitis, in elderly persons, 552
Decrescendo phenomenon, in irritant dermatitis, 366–367
Delaviridine, reactions to, in HIV infection, 330
Dendritic cells, in allergic contact dermatitis, 389
Dental impression compounds, contact stomatitis from, 477
Dental products, contact stomatitis from, 474
Denture sore mouth syndrome, 479
Dentures, contact stomatitis from, 478–479
Depression, asthma with, 596, 615
Dermatitis, actinic, 465–468
contact. See *Contact dermatitis.*
nail polish, 133
of eyelids, 118, 123
photo-, in elderly persons, 524
seborrheic, of eyelids, 108–109
Dermatitis hiemalis, in elderly persons, 527
Dermatofibromas, in elderly persons, 541
Dermatologic disorders, of eyelids. See *Eyelids, dermatologic disorders of.*
Dermatology, basic, 103–108
Dermatomyositis, of eyelids, 110–111, 118
pulmonary involvement in, in elderly persons, 734
Dermatophagoides. See *Dust mites.*
Dermatophytosis, versus contact dermatitis, 528–529
Dermis, description of, 103
Desensitization, in drug reactions, in HIV infection, 330–334
Dexamethasone, in vernal conjunctivitis, 46
Diabetes mellitus, from corticosteroids, in elderly persons, asthma and, 596, 708–710, 717–718
Diffuse infiltrative lymphadenopathy syndrome, 93
Digoxin, in cardiovascular disease, in elderly persons, with asthma, 633
Diltiazem, in cardiovascular disease, in elderly persons, with asthma, 632
Diphtheria toxoid, in HIV infection, 202
DNA synthesis, in epidermal permeability barrier disruption, 420
Drug(s), additives to, contact stomatitis from, 478
as contact dermatitis inhibitors, 408
contact dermatitis and, 134–135
Drug reactions, in elderly persons, contact dermatitis, 523–526
cutaneous, 529–530
in rheumatic disease, pulmonary involvement in, 738–739
in systemic lupus erythematosus, 731
photocontact dermatitis, 453, 460
rhinitis, 545
in HIV infection, **319–338**
acyclovir, 334
antimycobacterials, 329, 334
ciprofloxacin, 330
classification of, 320
clindamycin, 327, 333

Drug reactions *(Continued)*
concurrent illness and, 323
cutaneous, 322
dapsone, 326–327, 332
definitions in, 320
desensitization in, 330–334
diagnosis of, 324–325
mechanisms of, 320–322
non-nucleoside reverse transcriptase inhibitors, 330
patient-related factors in, 323–324
penicillins, 328, 334
pentamidine, 327–328, 333–334
pneumonitis in, eosinophilia in, 221
skin eruptions in, 249
sulfadiazine, 332
sulfonamides, 325–326
thalidomide, 329
trimethoprim-sulfamethoxazole, 325–326, 331–332
types of, 322–323
zidovudine, 328
Dry eye syndrome, **89–102**
causes of, 91–92
complications of, 100–101
description of, 89
signs of, 93–95
symptoms of, 93
treatment of, 96–100
Dry skin, in elderly persons, 527
pruritus in, 530
irritant contact dermatitis in, 371
Dust mites, atopic dermatitis in, clinical features of, 432–435
patch testing in, 437–439
role of, 435–437
Dyshidrotic eczema, 369
Dyspnea, in asthma, in elderly persons, 577–580
with cardiovascular disease, 628–630

Economic impact, of contact dermatitis, 353
Eczema. See also *Contact dermatitis.*
dyshidrotic, 369
from orthopedic implants, 492–495
housewife's, in elderly persons, 526–527
in atopic dermatitis, 433, 435
winter (dermatitis hiemalis), in elderly persons, 527
Eczema craquelé, in elderly persons, 527
Edema, periorbital, in acute ocular allergy, 23
Elderly persons, allergic disease in, **513–520**. See also *Asthma, in elderly persons.*
demographics of, 513, 515–516
immunology of, 516–519
physiologic changes of aging and, 516
types of, 513–514
asthma in. See *Asthma, in elderly persons.*
demographics of, 515–516
photodermatitis in, 524
rheumatic disease in, pulmonary involvement in, **727–744**
rhinitis in, 543–547
sinusitis in, 547–554
skin disorders in, **521–541**
Electrocardiography, in asthma, in elderly persons, 566
Elgiloy, in implants, 490
ELISA (enzyme-linked immunosorbent assay), for HIV, 190–191
Embolism, pulmonary, in HIV infection, wheezing in, 258–259
versus asthma, in elderly persons, 569–570
Emedastine, in allergic conjunctivitis, 29
Emphysema, versus asthma, in elderly persons, 567–568, 584
Encephalitozoon sinusitis, in HIV infection, 273, 276
Enzyme-linked immunosorbent assay, for HIV, 190–191
Eosinophil(s), HIV infection of, 211–212
measurement of, in asthma, 566
in HIV infection, 212–213
Eosinophilia, in elderly persons, in asthma, 582
with nonallergic rhinitis, 545
in HIV infection, **207–228**
asthma and, 254–255
differential diagnosis of, 215–217
eosinophil physiology and, 207–211
evaluation of, 212–216
in allergy, 218–219
in collagen vascular disease, 219–220
in dermatologic disease, 222–223
in gastrointestinal disease, 223
in helminthic infections, 215, 218
in idiopathic hypereosinophilic syndrome, 219, 224
in myeloproliferative disease, 220
in neoplasia, 220
in nonparasitic infections, 218
in respiratory disease, 220–222
pathogenesis of, 211–212
treatment of, 224
Eosinophilic fasciitis, in HIV infection, 220
Epidermal permeability barrier, **417–430**
disruption of, causes of, 426
pathogenic consequences of, 425–429
response to, 419–421
homeostasis of, signaling molecules in, 421–425
metabolic activity of, 418–419
structure of, 418

Epidermis, description of, 103
Epidermolysis bullosa acquisita, 148–150
clinical presentation of, 148–149
course of, 150, 153
laboratory investigations in, 149–150
pathogenesis of, 150, 153
treatment of, 150, 153
Epinephrine, in contact stomatitis, 483
Erosion, of eyelids, 105
Erysipelas, of eyelids, 118
E-selectin, in irritant contact dermatitis, 408–409
Esophagus, acid reflux into. See *Gastroesophageal reflux.*
Estrogen replacement therapy, for glucocorticoid-induced osteoporosis, 707
Etidronate, in glucocorticoid-induced osteoporosis, 706
Excoriations, of eyelids, 105
Exercise, in elderly persons, **607–626**
lung function versus disability and, 607–609
physiology of aging and, 609–610
response to training, 610–611
with asthma, 611, 613–614
exercise-induced bronchospasm in, 616–617
physical activity level in, 614–616
preoperative, for lung volume expansion, 666
training program for, 618–621
Experimental autoimmune uveitis, mast cells in, 12
Exsiccation eczamatid irritant contact dermatitis, 371
Eye(s). See also under *Ocular.*
contact dermatitis of, **131–138**
diseases of, mast cells in, 9–12
dry, **89–102**
inflammation of, pediatric concerns of, **161–177**
irritation of, causes of, **131–138**
normal, mast cells in, 8–9
Eyelids, dermatologic disorders of, **103–129**
allergic, 106
allergic contact dermatitis, 118
angioedema, 116–117
atopic skin, 123–124
basal cell carcinoma, 114, 119–120
chalazion, 118–119
clinical lesions, 104–105
comedones, 113
contact dermatitis, acute, 121–122
chronic, 123–126
dermatitis, 123
dermatomyositis, 110–111, 118
edema, 116–118
erosion, 105
erysipelas, 118
excoriations, 105
flat warts, 115
genetic, 105–106
hemangiomas, 121
herpes simplex virus infection, 124–125
herpes zoster virus infection, 125–126
human papillomavirus infection, 115
infection, 106
lichenification, 105
lipoid proteinosis, 116
macular lesions, 108–111
macules, 104
milia, 115–116
molluscum contagiosum, 114–115
nevus, 120–121
nevus of Ota, 111
nodules, 105, 118–121
papules, 104, 111–116
pathogenesis of, 105–107
plaques, 111–116
port-wine stains, 111
primary lesions in, 104–105
pustules, 104
rosacea, 112–113
sarcoid, 121
scales, 105
seborrheic dermatitis, 108–111
seborrheic keratosis, 112
secondary lesions in, 105
squamous cell carcinoma, 114, 119–120
syringomas, 114
testing of, 107
treatment of, 107–108
trichinosis, 118
tumors, 106, 118–121
ulcers, 105
varicella infection, 125–126
vesicles, 104, 121–123
vitiligo, 109–110
wheals, 104–105, 116–118
xanthelasma, 111–112

Famotidine, in gastroesophageal reflux, in elderly persons, 649–650
Fasciitis, eosinophilic, in HIV infection, 220
Fever, in elderly persons, 517
Fibrosis, pulmonary, in polymyositis, in elderly persons, 734
in rheumatoid arthritis, in elderly persons, 729
Flat warts, of eyelids, 115
Flunisolide, in asthma, endocrine-metabolic effects of, in elderly persons, 710–718
Fluorometholone, in allergic conjunctivitis, 28–29

Fluticasone propionate, in asthma, endocrine-metabolic effects of, in elderly persons, 710–718
Folliculitis, eosinophilic pustular, in HIV infection, 222–223, 245–248
Forced expiratory volume in 1 second, in asthma, in elderly persons, 562–563
Formaldehyde, in wearing apparel, contact dermatitis from, 524
Formalin-resistant mast cells, 6
Formalin-sensitive mast cells, 5–6
Functional endoscopic sinus surgery, in sinusitis, 553
Functional heterogeneity, 6–7
Fundoplication, in gastroesophageal reflux, in elderly persons, 650–651, 654–655
Fungal infections, asthma and, in elderly persons, 681–682, 692
  sinusitis, in elderly persons, 549
    in HIV infection, 276–277
  skin, versus contact dermatitis, 528–529

Gastroesophageal reflux, asthma and, in elderly persons, 570–571, 594–595, **645–658**
    clinical features of, 647–648
    evaluation of, 648–649
    incidence of, 647
    pathogenesis of, 645–649
    treatment of, 649–656
Gastrointestinal disorders, in HIV infection, eosinophilia in, 223
  versus asthma, in elderly persons, 570–571
Gender, as factor in vernal conjunctivitis, 34
Genetic factors, in drug reactions, 324
Genetic lesions, of eyelids, 105–106
Genital skin disorders, in elderly persons, 531
Giant cell arteritis, pulmonary involvement in, in elderly persons, 735–736
Giant papillary conjunctivitis, **53–73**
  description of, 53
  epidemiology of, 59–62
  examination for, 55
  histopathology of, 62–64
  mast cells in, 11
  pathophysiology of, 66–67
  signs and symptoms of, 53–55
  stages of, 55–59
  treatment of, 67–70
  versus vernal conjunctivitis, 41
Glaucoma, congenital, in children, 172–173
  drugs for, asthma from, 592–593
Gloves, for contact dermatitis prevention, 445
  rubber chemicals in, contact stomatitis from, 480–481
Glucocorticoids, contact dermatitis from, 525
  in asthma, in elderly persons, **701–726**
    bone metabolic effects of, 704–708, 715–717
    glucose metabolic effects of, 708–710, 717–718
    gonadal effects of, 708
    inhaled, 710–718
    pituitary-adrenal effects of, 702–704, 712–715
    systemic, 702–710
  in mast cell–mediated disease, 82
Glucose metabolism, glucocorticoid effects on, in elderly persons, 708–710, 717–718
Gold, contact stomatitis from, 476–477
Gonadal effects, of glucocorticoids, in elderly persons, 708
Granule-associated mediators, preformed, 2–4
Granulocyte-macrophage colony-stimulating factor, in contact dermatitis, 393, 408–409
  in epidermal permeability barrier, 422, 424
  in Langerhans cell survival, 391
Guaifenesin, in sinusitis, in HIV infection, 285

Haemophilus influenzae vaccine, in asthma, in elderly persons, 683
  in HIV infection, 201–202
Hair dyes, contact dermatitis from, 524
Handwashing, in viral infection prevention, in asthma, in elderly persons, 684
Hardening, of skin, in irritant contact dermatitis, 428–429
Hay fever conjunctivitis, 24
  versus vernal conjunctivitis, 40–41
Heat shock proteins, in irritant contact dermatitis, 410–411
Heliotrope, of eyelids, 110–111, 118
Helminthic infections, in HIV infection, eosinophilia in, 215, 218
Hemangiomas, of eyelids, 121
Hemorrhage, pulmonary, in systemic lupus erythematosus, in elderly persons, 732
Hepatitis A, vaccination for, in HIV infection, 200–201
Hepatitis B, vaccination for, in HIV infection, 199–200
Herpes simplex virus infections, in children, 170–171

of eyelids, 124–125
Herpes zoster virus infections, of eyelids, 125–126
Heterogeneity, functional, 6–7
mast cell, 5–7
pharmacologic, 7
phenotypic, 5–6
High-resolution computed tomography, in asthma, in elderly persons, 566
Hill posterior gastropexy, in gastroesophageal reflux, in elderly persons, 651
Histamine–2 receptor antagonists, in gastroesophageal reflux, in elderly persons, 649–652
response to, in asthma, 595
Histamine receptors, in ocular allergy, 75–76
HIV infection. See *Human immunodeficiency virus infection.*
Hormone replacement therapy, for glucocorticoid-induced osteoporosis, 707
Housewife's eczema, in elderly persons, 526–527
Human immunodeficiency virus, antibodies to, appearance of, 187
formation of, 233
tests for, 190–192
culture of, 191
measurement of, 191
Human immunodeficiency virus infection, allergen immunotherapy in, 299–300, **303–317**
allergic rhinitis in, 218, **291–301**
allergist role in, 192–193
asthma in, 218, 221, **253–266**
asymptomatic, 187–188
classification of, 186
clinical course of, 232–233
constitutional symptoms of, 190
drug reactions and sensitization in, 221, 249, **319–338**
eosinophilia in, **207–228**
epidemiology of, 185–186
immunization in, **195–206**, 309–310
immunoglobulin E synthesis in, **229–238**
immunologic changes in, 232–233
lymphadenopathy in, 190
mucocutaneous manifestations of, 189–190
pathophysiology of, 304–306
primary, signs and symptoms of, 186–187
prognosis of, versus immunoglobulin E levels, 233–234
pruritus in, **239–251**
signs and symptoms of, **185–194**, 232–233
sinusitis in, 190, **267–289**
allergic rhinitis with, 298–299
skin conditions in, 189
stages of, 186–188
tests for, 190–192
transmission of, reduction of, 189
treatment of, early diagnosis importance in, 188–189
in primary stage, 187
Human papillomavirus (HPV), of eyelids, 115
Hydroxyzine, in vernal conjunctivitis, 44
Hypereosinophilic syndrome, idiopathic, in HIV infection, 219, 224
Hypergammaglobulinemia, in HIV infection, 235
Hyperglycemia, from glucocorticoids, in elderly persons, 708–710, 717–718
Hyper-immunoglobulin E-like syndrome, in HIV infection, 234–236
Hyperimmunoglobulinemia E, in HIV infection, 234–236
Hypersensitivity vasculitis, pulmonary involvement in, 738
Hypertension, asthma with, 593–594
pulmonary, in systemic lupus erythematosus, 732–733
Hyposensitization/immunotherapy, in vernal conjunctivitis, 48
Hypothalamic-pituitary-adrenal axis, glucocorticoid effects on, in elderly persons, 702–704, 712–715

Ice therapy, for contact stomatitis, 483
Idiopathic hypereosinophilic syndrome, in HIV infection, 219, 224
Immunization, in asthma, in elderly persons, 683
in HIV infection, **195–206**, 309
antibody responses in, 196–197
bacillus Calmette-Guerin, 203
diphtheria toxoid, 202
for travelers, 203
Haemophilus influenzae type B, 201–202
hepatitis A, 200–201
hepatitis B, 199–200
HIV activation in, 198
immunoglobulin preparations in, 203
influenza, 199
measles-mumps-rubella, 201
pneumococcal, 198–199
poliovirus, 202
tetanus toxoid, 202
varicella-zoster virus, 202–203
versus allergen immunotherapy, 309–310
Immunoglobulin(s), postexposure, in HIV infection, 203
Immunoglobulin D, in HIV infection, 294

Immunoglobulin E, synthesis of, **229–238**
in atopic dermatitis, 434
in HIV infection, 233–236
in allergic rhinitis, 294–296
in sinusitis, 279–281
normal regulation of, 229–232
Immunology, of aging, 516–519, 672–674
Immunomodulation, in mast cell–mediated disease, 82–83
Immunophilins, in ocular allergy, 84
Immunosenescence, 673–674
Immunosuppressive agents, in vernal conjunctivitis, 47
Immunotherapy, allergen. See *Allergen immunotherapy.*
for vernal conjunctivitis, 48
Implants, metallic. See *Metals, in implants.*
Impressions, dental, compounds for, contact stomatitis from, 477
Infections, airway, versus asthma, in elderly persons, 591
dermatologic disorders due to, 106
in vernal conjunctivitis, 47–48
lower respiratory. See *Pneumonia.*
Inflammation, eosinophils in, 210–211
in asthma, in HIV infection, 254–255
ocular, pediatric concerns of, **161–177**
Inflammatory bowel disease, pulmonary involvement in, in elderly persons, 730
Influenza, asthma and, in elderly persons, 691–692
immunization for, in HIV infection, 199
Inhalers, in asthma, in elderly persons, 601
cardiovascular effects of, 634–637
side effects of, 710–718
Insulin resistance, from corticosteroids, in elderly persons, asthma and, 596, 708–710, 717–718
Intercellular adhesion molecules, in contact dermatitis, 362, 394, 408–409
Interferon-gamma, in contact dermatitis, 394, 409
in epidermal permeability barrier, 422, 425
in immunoglobulin E synthesis, 230–232
in HIV infection, 235
Interleukin(s), in contact dermatitis, 392–394, 408–409
in epidermal permeability barrier, 422–425
in disruption, 425, 427
in immunoglobulin E synthesis, 230–232
production of, in HIV infection, 232–233, 235
receptors for, in epidermal permeability barrier, 425
Interleukin–1, in Langerhans cell survival, 391
Interleukin–4, in atopic dermatitis, 433
Interleukin–10, in contact dermatitis, 408
Interleukin–15, in T-lymphocyte amplification, in irritant contact dermatitis, 411–412
Interstitial lung disease, in HIV infection, eosinophilia in, 221–222
in systemic sclerosis, in elderly persons, 733–734
versus asthma, in elderly persons, 569
Interstitial nephritis, in HIV infection, eosinophilia in, 223
Ipratropium, in asthma, in elderly persons, 599
in rhinitis, in elderly persons, 547
Irritant contact dermatitis. See *Contact dermatitis, irritant.*
Irritant reaction (acute irritant contact dermatitis), 366–368
Isosporiasis, in HIV infection, eosinophilia in, 218
Isotretinoin, in eosinophilic folliculitis, 248
Itching. See *Pruritus (itching).*
Itch-scratch-itch cycle, 528
Itraconazole, in eosinophilic folliculitis, 247
in fungal pneumonia, in asthma, in elderly persons, 692
Ivermectin, in scabies, 248–249

Jewelry, allergic reactions to, 487–488
Jones test, for dry eye evaluation, 95–96
Junctional nevi, in elderly persons, 538

Kaposi's sarcoma, in HIV infection, in respiratory system, 258
Kawasaki's disease, in children, 173–174
Keratinocytes, cytokines of, in contact dermatitis, 362–363, 391–397, 408–409, 411–412
in Langerhans cell survival, 391
heat shock proteins of, in irritant contact dermatitis, 411
intercellular adhesion molecules of, in contact dermatitis, 394
interferon-gamma of, in contact dermatitis, 394
major histocompatibility complex antigens of, in contact dermatitis, 394–395
Keratitis sicca, **89–102**
complications of, 100–101
Jones test for, 95–96
Schirmer test for, 95–96
signs of, 93–95
symptoms of, 93
treatment of, 96–100
Keratoacanthomas, 535–536

Keratosis, actinic, in elderly persons, 538
seborrheic, in elderly persons, 538
of eyelids, 112
Kerosene, contact dermatitis from, 360
Ketorolac, in allergic conjunctivitis, 28
in vernal conjunctivitis, 46
Koebnerization, in atopic dermatitis, 433, 435

Lacerations, irritant contact dermatitis after, 371–372
Laennec Working Staging System, for HIV infection, 186
Langerhans cells, in atopy, 432
in contact dermatitis, 386–391, 407–408
in photocontact dermatitis, 457
irritants effects on, 361–362
metal effects on, 499
Late-phase reaction, conjunctival, in allergic conjunctivitis, 26–27
Latex products, contact dermatitis from, 525
contact stomatitis from, 480–481
Lentigo maligna, in elderly persons, 537
Lentigos, in elderly persons, 538
Leukemia, in HIV infection, eosinophilia in, 220
Leukotriene antagonists, in asthma, in elderly persons, cardiovascular effects of, 639–640
Leukotriene receptor antagonists, in asthma, in elderly persons, 600
Levocabastine, in allergic conjunctivitis, 28
in mast cell–mediated disease, 78–79
in vernal conjunctivitis, 44
Lichen sclerosus et atrophicus, in elderly persons, 531
Lichen simplex chronicus, versus contact dermatitis, 528
Lichenification, of eyelids, 105
Light sensitivity, dermatitis in. See *Photocontact dermatitis.*
Linear IgA disease, 150–153
clinical presentation, 151
laboratory investigations, 152–153
Lipid(s), in stratum corneum, 419–421
Lipid mediators, 4–5
Lipoid proteinosis, of eyelids, 116
Lipoxygenase inhibitors, in vernal conjunctivitis, 46
Lodoxamide, in allergic conjunctivitis, 28
in mast cell–mediated disease, 80–81
in vernal conjunctivitis, 45
Loffler's syndrome, in HIV infection, eosinophilia in, 221
Loratidine, in asthma, in elderly persons, cardiovascular effects of, 640
Loteprednol etabonate, in allergic conjunctivitis, 29
Louis-Bar syndrome, in children, 175–176
Lung, cancer of, in HIV infection, wheezing in, 258
versus asthma, in elderly persons, 570
expansion of, preoperative exercises for, in asthma, in elderly persons, 666
fibrosis of, in polymyositis, in elderly persons, 734
in rheumatoid arthritis, in elderly persons, 729
function of, versus physical disability, 607–609
hemorrhage of, in systemic lupus erythematosus, in elderly persons, 732
interstitial disease of, in HIV infection, eosinophilia in, 221–222
in systemic sclerosis, in elderly persons, 733–734
versus asthma, in elderly persons, 569
nodules in, in rheumatoid arthritis, in elderly persons, 730
obstructive disease of. See *Asthma; Chronic obstructive pulmonary disease.*
rheumatic disease effects on, in elderly persons, **727–744**
vasculitis of, in temporal arteritis, 735–736
Lupus pneumonitis, in elderly persons, 732
Lymphadenopathy, in HIV infection, 190
Lymphocyte-mediated ocular disease, 83–84
Lymphocytic interstitial pneumonitis, in HIV infection, eosinophilia in, 222
Lymphoma, in HIV infection, eosinophilia in, 220
pulmonary dysfunction in, 261
sinusitis in, 277
Lymphopenia, in HIV infection, 192

Macular lesions, of eyelids, 104, 108–111
Major histocompatibility complex antigens, of keratinocytes, in contact dermatitis, 394–395
of Langerhans cells, 387
Malignant melanoma, in elderly persons, 536–540
Malnutrition, in elderly persons, immunologic effects of, 674–675
in HIV infection, immunoglobulin E levels and, 236
Manifestation threshold, in contact dermatitis, 370–371
Mascara, eye irritation due to, 132
Mast cell(s), connective-tissue, 6
degranulation of, in atopic dermatitis, 433
differentiation of, 7–8

Mast cell(s) *(Continued)*
formalin-resistant, 6
formalin-sensitive, 5–6
heterogeneity of, 5–7
in allergic conjunctivitis, 19–20
in diseases of eye, 9–12
in normal eye, 8–9
mucosal, 5
ocular, **8–12**
Mast cell stabilizers, in giant papillary conjunctivitis, 67–68
in mast cell–mediated disease, 79–81
in vernal conjunctivitis, 45
Mast cell–mediated disease, treatment of, 76–83
Maximal oxygen consumption, aging effects on, 609–610
Measles, vaccination for, in HIV infection, 201
Melanoma, malignant, in elderly persons, 536–540
Meningitis, in HIV infection, eosinophilia in, 223
Mercury, contact stomatitis from, 475–476
Metabolic disorders, drug reactions in, 321–322
Metals, contact stomatitis from, 474–477
in implants, allergic reactions to, **487–504**
clinical features of, 491–498
cutaneous, 492–495, 498
diagnosis of, 499–501
loosening and, 495–496
patch testing in, 496–497, 500–501
pathogenesis of, 498–499
prevalence of, 490–491
treatment of, 501
alloys for, 488–489
dynamic, 491
historical background of, 488
static, 491
types of, 487–490
Metastasis, to skin, 539–540
Metered-dose inhalers, in asthma, in elderly persons, 601, 635
Methacholine challenge test, in asthma, in HIV infection, 259
with gastroesophageal reflux, 646–647
Methotrexate, pneumonitis from, 739
Metronidazole, in eosinophilic folliculitis, 247–248
Microscopic angiitis, pulmonary involvement in, 738
Milia, of eyelids, 115–116
Minimal erythema dose, in photopatch testing, 461–463
Mites, dust. See *Dust mites.*
Mohs micrographic surgery, in skin cancer, 536
Molluscum contagiosum, of eyelids, 114–115
Mouth, angular cheilitis of, in elderly persons, 530–531
mucous membrane contact dermatitis of. See *Contact stomatitis.*
Mouth-care products, contact stomatitis from, 474, 478
Mucociliary transport, impaired, sinusitis and, in elderly persons, 548–549
in HIV infection, 282–283
Mucosal mast cells, 5–6
Mumps, vaccination for, in HIV infection, 201
Mycoplasma pneumoniae pneumonia, in asthma, in elderly persons, 690
Myeloproliferative disease, in HIV infection, eosinophilia in, 220

Naevus flammeus, of eyelids, 111
Nail polish dermatitis, 133
Naphazoline hydrochloride, in allergic conjunctivitis, 27
NARES (nonallergic rhinitis with eosinophilia), in elderly persons, 545
Nasal polyps, in elderly persons, 545
asthma and, 576, 582
Nasal sprays, in allergic rhinitis, in HIV infection, 293
Nasolacrimal duct obstruction, 171–172
Nedocromil sodium, in mast cell–mediated disease, 81
in vernal conjunctivitis, 45
Neonates, conjunctivitis in, 168–169
Neoplasia, in HIV infection, eosinophilia in, 220
sinusitis in, 277–278
Nephritis, interstitial, in HIV infection, eosinophilia in, 223
Neurodermatitis, versus contact dermatitis, 528
Neurotic excoriations, of eyelids, 105
Neutral proteases, 3–4
Nevi, junctional, in elderly persons, 538
of eyelids, 120–121
Nevirapine, reactions to, in HIV infection, 330
Nevus of Ota, 111
Nickel, allergic reactions to, 491
cutaneous, 492
patch testing for, 496–497
cell degranulation from, 499
contact stomatitis from, 476
in implants, allergic reactions to, 487–488
in stainless steel, 489
Nissen fundoplication, in gastroesophageal reflux, in elderly persons, 651, 655
Nitrates, in cardiovascular disease, in elderly persons, with asthma, 631

Nizatidine, in gastroesophageal reflux, in elderly persons, 649–650
Nodular melanoma, in elderly persons, 538
Nodules, of eyelids, 105, 118–121
  pulmonary, in rheumatoid arthritis, in elderly persons, 730
Nonallergic rhinitis with eosinophilia, in elderly persons, 545
Nonerythematous irritant contact dermatitis, 372
Non-nucleoside reverse transcriptase inhibitors, reactions to, in HIV infection, 330
Nonsteroidal anti-inflammatory drugs, in eyedrops, asthma from, 592–593
  in mast cell–mediated disease, 81–82
  in vernal conjunctivitis, 45–46
  sensitivity to, in elderly persons, 596–597
Norwegian scabies, in HIV infection, 248–249
Nosocomial sinusitis, in elderly persons, 553
Nutrition, in elderly persons, immunologic effects of, 674–675
  in HIV infection, immunoglobulin E levels and, 236

Occupational dermatitis, causes of, 365–366
  clinical syndromes of, 365–375
  economic impact of, 353
  epidemiology of, 346–351
  prevention of, 351–353
    education for, 447–448
    protective gloves and clothing in, 445
    screening programs for, 447
    skin care products in, 445–447
    technical measures in, 444–445
Ocular allergy, avoidance of allergens in, 76
  histamine receptors in, 75–76
  immunophilins for, 84
  treatment of, **75–87**
Ocular challenge test, in vernal conjunctivitis, 43
Ocular mast cell(s), **8–12**
  in diseases of eye, 9–12
  in normal eye, 8–9
  mediators of, **1–8**
Ofuiji's disease (eosinophilic pustular folliculitis), in HIV infection, 222–223, 245–248
Old man's drip, 544
Olopatadine, in allergic conjunctivitis, 29
Omeprazole, in gastroesophageal reflux, in elderly persons, 650, 652–654
Ophthalmic preservatives, eye irritation due to, 135
Opportunistic pathogens, in sinusitis, in HIV infection, 273, 276–277
Orthopedic implants, metals used for. See *Metals, in implants.*
Osteoporosis, from glucocorticoids, in elderly persons, 704–708, 715–717
Otitis media, in allergic rhinitis, in HIV infection, 292
Oxygen consumption, maximal, aging effects on, 609–610
Oxymetazoline, in mast cell–mediated disease, 77

p24 antigen, measurement of, 191
Paper, eye irritation due to, 135
Papular eruptions, in HIV infection, 244–250
Papules, of eyelids, 104, 111–116
Paranasal sinusitis. See *Sinusitis.*
Paraphenylenediamine, in hair dyes, contact dermatitis from, 524
Patch testing, in atopic dermatitis, in dust mite allergy, 437–439
  in contact dermatitis, in elderly persons, 528
  in contact stomatitis, 482
  in metal allergic reactions, 496–497, 500–501
  in photocontact dermatitis, 460–465
Peak expiratory flow, in asthma, in elderly persons, 563, 565
Pediatric patients, allergic conjunctivitis in, 162
  ataxia-telangiectasia in, 175–176
  bacterial conjunctivitis in, 164–166
  congenital glaucoma in, 172–173
  herpes simplex virus conjunctivitis in, 170–171
  HIV infection in, allergic rhinitis in, 297–298
    sinusitis in, 268, 270
  Kawasaki's disease in, 173–174
  nasolacrimal duct obstruction in, 171–172
  ocular inflammation in, **161–177**
  uveitis in, 174–175
  viral infections in, 169–170
Penicillins, reactions to, in HIV infection, 328, 334
Pentamidine, reactions to, in HIV infection, 327–328, 333–334
  wheezing from, 259, 261
Pentoxifylline, in contact dermatitis, 408
Perennial allergic conjunctivitis, 25
Perlèche, in elderly persons, 530–531
Permeability barrier, epidermal. See *Epidermal permeability barrier.*

Persistent light reactions, of skin, 465–468
Pharmacologic heterogeneity, 7
Pheniramine, in allergic conjunctivitis, 27
Phenotypic heterogeneity, 5–6
Photoallergy, to systemic agents, 451–452
Photoantigens, in photocontact dermatitis, 455–457
for photopatch testing, 460, 463–464
Photocontact dermatitis, **451–470**
agents causing, 380, 453–454, 459–460
allergic, 380, 451–452, 454–460
differential diagnosis of, 458
animal studies of, 456–457
chronic, 465–468
clinical features of, 452, 458
diagnosis of, 452, 454
drugs causing, 453, 460
epidemiology of, 457–458
irritant, 380, 451–452, 454
mechanism of action of, 451
pathophysiology of, 454–457
persistent light reactions in, 465–468
photopatch testing in, 460–465
transient light reactions in, 465, 468
types of, 451
Photodermatitis, in elderly persons, 524
Phototoxicity, to systemic agents, 451–452
Pituitary-adrenal effects, of glucocorticoids, in elderly persons, 702–704, 712–715
Plants, eye irritation due to, 135–136
Plaques, of eyelids, 111–116
Pleural disease, in rheumatoid arthritis, in elderly persons, 729
in systemic lupus erythematosus, in elderly persons, 731–732
Pneumococcal vaccine, in asthma, in elderly persons, 683
in HIV infection, 198–199
Pneumocystis carinii pneumonia, in HIV infection, asthma and, 255, 258
Pneumonia, in elderly persons, asthma with, **671–700**
age effects in, 676–677
Aspergillus, 681–682, 692
atypical, 690
bacterial, 678–679, 690–691
demographics of, 671–672
diagnosis of, 685–686
fungal, 681–682, 692
hospitalization criteria for, 686–687
postoperative, 661–662
prevention of, 683–684
treatment of, 687–692
viral, 679–681, 691–692
causes of, 673–674
host defenses against, 672–676
mortality in, 672
nutritional deficiencies and, 674–675
versus asthma, 591
in HIV infection, 323
asthma and, 255, 258
eosinophilic, 221, 323
Pneumonitis, lupus, in elderly persons, 732
Polio vaccine, in HIV infection, 202
Polyarteritis nodosa, microscopic, pulmonary involvement in, 738
Polymyalgia rheumatica, pulmonary involvement in, in elderly persons, 734–735
Polymyositis, pulmonary involvement in, in elderly persons, 734
Polyps, nasal, in elderly persons, 545, 576, 582
Port-wine stains, of eyelids, 111
Postoperative complications, prevention of. See *Presurgical preparation.*
Postural chest drainage, preoperative, in asthma, in elderly persons, 666
Prednisone, in contact stomatitis, 483
in metal allergic reactions, 501
Preformed granule-associated mediators, 2–4
Preservatives, contact stomatitis from, 478
Presurgical preparation, in asthma, in elderly persons, **659–670**
airway resistance minimizing in, 666–667
anticholinergic drugs in, 668
beta-adrenergic agent inhalation in, 667
corticosteroids in, 668
lung aging and, 660
lung expansion exercises in, 666
methylxanthine inhalation in, 667
postoperative pulmonary function impairment and, 660–662
psychologic, 669
pulmonary function testing in, 663–665
secretion clearance in, 666
Propafenone, in cardiovascular disease, in elderly persons, with asthma, 632
Proteases, neutral, 3–4
Protective gloves and clothing, for contact dermatitis prevention, 445
Proteoglycans, 2–3
Pruritic papular eruption of HIV, 249–250
Pruritus (itching), in allergic conjunctivitis, 21
in atopic dermatitis, 434–435
in elderly persons, 530
in HIV infection, **239–251**
algorithmic approach to, 240–244
in acne vulgaris, 249
in drug reactions, 249
in eosinophilic folliculitis, 245–248
in papular eruptions, 244–250
in scabies, 248–249
treatment of, 243–244

in vernal conjunctivitis, 34
Pseudallescheria boydii sinusitis, in HIV infection, 276–277
Pseudomonas aeruginosa sinusitis, in HIV infection, 273
Psoriatic arthritis, pulmonary involvement in, in elderly persons, 730
Public health impact, of contact dermatitis, **345–357**
costs of, 353
magnitude, 347–351
measures of, 345–346
preventability and, 351–353
prognosis and, 351–353
statistical data on, 346–347
Pulmonary artery involvement, in temporal arteritis, 736
Pulmonary embolism, in HIV infection, wheezing in, 258–259
versus asthma, in elderly persons, 569–570
Pulmonary function testing, in asthma, in elderly persons, 562–565, 577–580
preoperative, 663–665
in HIV infection, 259–262
Pulmonary hypertension, in systemic lupus erythematosus, in elderly persons, 732–733
in systemic sclerosis, in elderly persons, 733–734
Purpura, actinic, in elderly persons, 532
Pustular and acneiform irritant contact dermatitis, 372
Pustular folliculitis, eosinophilic, in HIV infection, 222–223, 245–248
Pustules, of eyelids, 104

Radioallergosorbent test (RAST), in vernal conjunctivitis, 41
Radiofrequency ablation, in cardiovascular disease, in elderly persons, with asthma, 632
Ranitidine, in gastroesophageal reflux, in elderly persons, asthma and, 595, 649–650, 652, 655–656
Rash, in HIV infection, eosinophilia in, 222
in drug reactions, 322, 325–330
Reactive arthritis, pulmonary involvement in, in elderly persons, 730
Reflex theory, of asthma in gastroesophageal reflux, 646–647
Reflux, gastroesophageal. See *Gastroesophageal reflux.*
Reflux theory, of asthma in gastroesophageal reflux, 646
Reiter's syndrome, pulmonary involvement in, in elderly persons, 730
Resins, for dental impressions, contact stomatitis from, 477
Respiratory diseases, in HIV infection, eosinophilia in, 220–222
infectious. See *Pneumonia.*
Reverse transcriptase inhibitors, reactions to, in HIV infection, 330
Rheumatic disease, pulmonary involvement in, in elderly persons, **727–744**
CREST syndrome, 733–734
dermatomyositis, 734
drug-induced, 738–739
polymyalgia rheumatica, 734–735
polymyositis, 734
rheumatoid arthritis, 728–730
spondyloarthropathy, 730
systemic lupus erythematosus, 731–733
systemic sclerosis, 733–734
systemic vasculitis, 736–738
temporal arteritis, 735–736
Rheumatoid arthritis, pulmonary involvement in, in elderly persons, 728–730
Rhinitis, allergic. See *Allergic rhinitis.*
in elderly persons, 543–547
allergic, 544
atrophic, 545–546
drug-induced, 545
idiopathic, 544–545
nonallergic, with eosinophilia, 545
polyps in, 545
Rhinitis medicamentosa, 77
Ribavirin, in viral pneumonia, in asthma, in elderly persons, 691–692
Rifampin, reactions to, in HIV infection, 329
Rimexolone, in allergic conjunctivitis, 29
RNA, human immunodeficiency virus, measurement of, 191
Rosacea, of eyelids, 112–113
Rubber, contact dermatitis from, 525
contact stomatitis from, 480–481
Rubella, vaccination for, in HIV infection, 201

Saline sprays, in sinusitis, in elderly persons, 552
Salmeterol, in asthma, in elderly persons, 599
Samter's triad, in elderly persons, 554
Sarcoid, of eyelids, 121
Scabies, in HIV infection, 248–249
versus contact dermatitis, 528
Scales, of eyelids, 105
Schirmer test, for dry eye evaluation, 95–96

Schulman's syndrome, in HIV infection, 220
Scratch testing, in metal allergic reactions, 500–501
Scutan, contact stomatitis from, 477
Seasonal allergic conjunctivitis, 24
  versus vernal conjunctivitis, 40–41
Sebaceous glands, hyperplasia of, versus basal cell carcinoma, 534
Seborrheic dermatitis, of eyelids, 108–109
Seborrheic keratosis, in elderly persons, 538
  of eyelids, 112
Selectins, in contact dermatitis, irritant, 408–409
Sensitization, contact, Langerhans cells in, 389
Sensory irritant contact dermatitis, 373
Sinusitis, in elderly persons, 547–554
    asthma and, 553–554, 582, 592
    diagnosis of, 549–551
    epidemiology of, 547
    microbiology of, 549
    pathophysiology of, 547–549
    treatment of, 551–554
  in HIV infection, 190, **267–289**
    allergic rhinitis with, 298–299
    allergic skin test reactivity in, 279–281
    atopy in, 278–279
    clinical features of, 269–272
    diagnosis of, 283
    epidemiology of, 267–269
    immunodeficiency in, 281–282
    microbiology of, 272, 276–277
    mucociliary dysfunction in, 282–283
    neoplasms with, 277–278
    opportunistic organisms in, 273
    pathophysiology of, 278–283
    prophylaxis for, 286
    radiography of, 270–271, 274–275, 283
    sphenoid, 271–272, 274–275
    treatment of, 284–286
Sjögren's syndrome, 92
Skin, atopic, of eyelids, 123–124
  contact dermatitis of. See *Contact dermatitis.*
  dry, in elderly persons, 527
      pruritus in, 530
    irritant contact dermatitis in, 371
  layers of, 103
  metastasis to, 539–540
  of elderly persons, 517
  tumors of, versus allergic disease, 532–541
Skin care products, protective, for contact dermatitis prevention, 445–447
Skin disorders. See also specific disorders.
  drug reactions, 322, 325–330
  from orthopedic implants, 492–495, 498
  in HIV infection, 189
    drug reactions, 325–330
    eosinophilia in, 222–223
  pruritus in. See *Pruritus.*
Skin tests, for allergy, in asthma, 565
  in HIV infection, 279–281
Smoking, in elderly persons, asthma and, 559, 583–584
      preoperative cessation of, 666–667
Sodium cromoglycate, in allergic conjunctivitis, effect on mast cells, 10–11
  in mast cell–mediated disease, 79
Sodium lauryl sulfate, contact dermatitis from, 360, 362
    preventive creams for, 446
Sotalol, in cardiovascular disease, in elderly persons, with asthma, 632
Sphenoid sinusitis, in HIV infection, 271–272, 274–275
Spirometry, in asthma, in elderly persons, 562–563
      preoperative, 666
Spondyloarthropathy, pulmonary involvement in, in elderly persons, 730
Spongiosis, in atopic dermatitis (koebnerization), 433, 435
  in contact dermatitis, 381
Squamous cell carcinoma, cutaneous, in elderly persons, 534–536
  of eyelids, 114, 119–120
Stainless steel, in implants, 489–490
Stomatitis, contact. See *Contact stomatitis.*
Stratum corneum. See also *Epidermal permeability barrier.*
  lipids in, 419–421
  metabolic activity of, 418–419
  structure of, 418
Streptococcus pneumoniae vaccine, in asthma, in elderly persons, 683
  in HIV infection, 198–199
Strongyloidiasis, in HIV infection, asthma and, 258
Subcutis, description of, 103
Subjective irritant contact dermatitis, 373
Sulfadiazine, reactions to, in HIV infection, 332
Sulfamethoxazole, toxicity of, 321
Sulfonamides, reactions to, in HIV infection, 325–326
Sunlight, actinic purpura from, 532
Sunscreens, photocontact dermatitis from, 459–460
Superficial spreading melanoma, in elderly persons, 537–538
Surgery, preparation for. See *Presurgical preparation.*
Syringomas, of eyelids, 114
Systemic lupus erythematosus, pulmonary involvement in, in elderly persons, 731–733

Systemic sclerosis, pulmonary involvement in, in elderly persons, 733–734

T lymphocytes, activation of, in contact dermatitis, irritant, 411–412
aging effects on, 517–518, 674
anergic, in contact dermatitis resolution, 395–398
antigen presentation to, Langerhans cells in, 389
auto-reactive, in contact dermatitis, 384, 410
CD4, in HIV infection, decline of, 232
measurement of, 192
sinusitis and, 281–282
cytokines from, in allergic dermatitis, 409–410
in irritant dermatitis, 409
eosinophil communication with, 210
gamma/delta receptor for, heat shock proteins and, 411
in immunoglobulin E synthesis, 230–232
in malnutrition, 674–675
infiltrates of, in allergic contact dermatitis, 384
Tantalum, in implants, 490
Tear film, 89–91
Tear substitutes, commercially available, 98
Temperature, environmental, subjective irritant contact dermatitis and, 373
Temporal arteritis, pulmonary involvement in, in elderly persons, 735–736
Terfenadine, in asthma, in elderly persons, cardiovascular effects of, 640
in mast cell–mediated disease, 77–78
Testosterone replacement therapy, for glucocorticoid-induced osteoporosis, 707
Tetanus toxoid, in HIV infection, 202
Thalidomide, reactions to, in HIV infection, 329
Theophylline, in asthma, in elderly persons, 599–600
cardiovascular effects of, 637–638
preoperative inhalation of, 667
Thermal injury, stomatitis in, 472
Thiacetazone, reactions to, in HIV infection, 329
Thrush, in HIV infection, 189–190
Timolol, in glaucoma, asthma from, 593
Tinea infections, versus contact dermatitis, 528–529
Titanium, in implants, 490
Tolerance, in contact dermatitis resolution, 395–398
Topical anesthetics, contact stomatitis from, 478
Toxic agents, systemic, phototoxicity in, 451
Toxic epidermal necrolysis, from sulfonamides, in HIV infection, 325
Toxicity, drug, in HIV infection, 321
Training, exercise, for asthma, in elderly persons, 618–621
Transforming growth factor, of keratinocytes, in contact dermatitis, 393–394
Transient light reactions, of skin, 465, 468
Traumatic irritant contact dermatitis, 371–372
Traumiterative irritant contact dermatitis, 371
Travelers, immunizations for, in HIV infection, 203
Tretinoin, irritant contact dermatitis from, 368
Triamcinolone, in asthma, endocrine-metabolic effects of, in elderly persons, 710–718
Trichinosis, of eyelids, 118
Trimethoprim-sulfamethoxazole, reactions to, in HIV infection, 325–326, 331–332
toxicity of, 321
Tryptase, description of, 3–4
Tuberculosis, drugs for, reactions to, in HIV infection, 329, 334
Tumor(s), obstruction from, versus asthma, 590–591
of eyelids, 106, 118–121
skin, versus allergic disease, 532–541
Tumor necrosis factors, in contact dermatitis, 393, 408–409
in epidermal permeability barrier, 422–425
in disruption, 427
receptors for, in epidermal permeability barrier, 425
Twitchy skin syndrome, in atopic dermatitis, 435

Ulcers, corneal shield, treatment, 47–48
of eyelids, 105
Ultraviolet light, in photopatch testing, 460–463
photocontact dermatitis from, 456–457
Uremia, stomatitis in, 472
Urticaria, contact, 380
from orthopedic implants, 492
Uveitis, experimental autoimmune, mast cells in, 12
in children, 174–175

Vaccination. See *Immunization*.

Vagal reflex, in asthma with gastroesophageal reflux, 646–647
Vanadium, in implants, 490
Vanishing lung syndrome, in systemic lupus erythematosus, in elderly persons, 732
Varicella-zoster virus infections, of eyelids, 125–126
  vaccine for, in HIV infection, 202–203
Vasculitis, in HIV infection, eosinophilia in, 219–220
  pulmonary, in temporal arteritis, 735–736
  systemic, pulmonary involvement in, in elderly persons, 736–738
Vasoconstrictors, in vernal conjunctivitis, 45
Venous lakes, in skin, in elderly persons, 540
Verapamil, in cardiovascular disease, in elderly persons, with asthma, 632
Vernal conjunctivitis, **33–51**
  age as factor in, 34
  allergy testing in, 41
  antigen avoidance in, 43
  clinical manifestations of, 34–38
  conjunctival examination in, 42
  conjunctival signs in, 35–36
  corneal involvement in, 36, 38
  description of, 33
  differential diagnosis of, 40–41
  epidemiology of, 34
  gender predilection for, 34
  geographic sites of, 34
  itching in, 34
  laboratory evaluation in, 41–43
  limbal, 36–37
  mast cells in, 11
  ocular challenge test in, 43
  pathogenesis of, 38–40
  patient history in, 33–34
  prognosis for, 48
  secondary infections in, 47–48
  tear evaluation in, 42–43
  treatment of, 43–48
  trophic ulcers in, 47–48
  versus atopic keratoconjunctivitis, 40
  versus drug hypersensitivity–related conjunctivitis, 41
  versus giant papillary conjunctivitis, 41
  versus seasonal allergic conjunctivitis, 40–41
Vernal shield ulcer, in vernal conjunctivitis, 36–37
Vesicles, of eyelids, 104, 121–123
Viral infections, in children, 169–170
  in elderly persons, asthma and, 679–681, 691–692
Vitallium, in implants, 489
Vitamin D, in glucocorticoid-induced osteoporosis, 706
Vitiligo, of eyelids, 109–110
Vulvar skin disorders, in elderly persons, 531

Warts, flat, of eyelids, 115
Wegener's granulomatosis, pulmonary involvement in, 737
  sinusitis in, 553
Well's disease, in HIV infection, 222
Western blot test, for HIV, 190–191
Wheals, of eyelids, 104–105, 116–118
Wheezing, in asthma, in elderly persons, 560–561, 577–580
    with cardiovascular disease, 628
  in HIV infection, differential diagnosis of, 255–259
Winter eczema (dermatitis hiemalis), in elderly persons, 527

Xanthelasma, of eyelids, 111–112
Xerosis. See *Dry skin.*

Zafirlukast, in asthma, in elderly persons, cardiovascular effects of, 639–640
Zidovudine, reactions to, in HIV infection, 328
Zileuten, in asthma, in elderly persons, cardiovascular effects of, 639–640
Zirconium, in implants, 490